James George Chopas Sells 1,096 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 1,096 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the transaction, the chief accounting officer now directly owns 48,138 shares of the company’s stock, valued at $1,464,839.34. This trade represents a 2.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

James George Chopas also recently made the following trade(s):

• On Friday, January 17th, James George Chopas sold 715 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $21,421.40.
• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total value of $22,472.10.

Apellis Pharmaceuticals Trading Down 2.5 %

Apellis Pharmaceuticals stock opened at $30.00 on Friday. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The stock has a 50-day simple moving average of $32.08 and a 200 day simple moving average of $33.18. The stock has a market capitalization of $3.73 billion, a P/E ratio of -14.78 and a beta of 0.94. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same quarter last year, the company posted ($1.17) EPS. The firm’s revenue was up 78.3% on a year-over-year basis. Analysts expect that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in APLS. Amalgamated Bank boosted its stake in Apellis Pharmaceuticals by 5.4% in the 2nd quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock valued at $268,000 after purchasing an additional 359 shares during the period. KBC Group NV raised its stake in Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after purchasing an additional 781 shares during the period. Wolverine Asset Management LLC acquired a new position in shares of Apellis Pharmaceuticals during the 3rd quarter worth approximately $27,000. Finally, True Wealth Design LLC bought a new position in shares of Apellis Pharmaceuticals during the third quarter worth approximately $27,000. Institutional investors own 96.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on APLS. Needham & Company LLC dropped their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Piper Sandler cut their price objective on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. HC Wainwright reiterated a “buy” rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Citigroup cut their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Morgan Stanley started coverage on Apellis Pharmaceuticals in a research report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Eight investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Apellis Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).